Acitretin modulates HaCaT cells proliferation through STAT1- and STAT3-dependent signaling

Area of Science:

• Dermatology
• Molecular Biology
• Cell Biology

Background:

• Psoriasis is a chronic inflammatory skin condition characterized by keratinocyte hyperproliferation.
• Acitretin is an effective retinoid therapy for psoriasis, but its precise molecular mechanisms remain incompletely understood.
• The JAK/STAT signaling pathway is implicated in keratinocyte differentiation and proliferation, and its dysregulation is observed in psoriasis.

Purpose of the Study:

• To investigate the relationship between keratinocyte proliferation and the JAK/STAT signaling pathway in psoriasis.
• To elucidate the molecular mechanisms by which acitretin modulates JAK/STAT signaling in keratinocytes.
• To determine if acitretin's therapeutic effects in psoriasis involve the inhibition of keratinocyte proliferation via this pathway.

Main Methods:

• Utilized HaCaT cells, an in vitro model for psoriasis, to study keratinocyte behavior.
• Administered acitretin to HaCaT cells to observe its effects on cell proliferation and signaling.
• Employed small interfering RNA (siRNA) targeting STAT1 and STAT3 (siRNA-STAT1, siRNA-STAT3) to specifically inhibit these signaling molecules.

Main Results:

• Acitretin significantly inhibited the proliferation of HaCaT cells.
• Both acitretin treatment and the inhibition of STAT1 or STAT3 using siRNA reduced HaCaT cell proliferation.
• Acitretin demonstrated a suppressive effect on the expression of STAT1 and STAT3 in HaCaT cells.

Conclusions:

• Acitretin may exert its therapeutic effects in psoriasis by inhibiting keratinocyte proliferation.
• The JAK/STAT signaling pathway, specifically involving STAT1 and STAT3, plays a crucial role in acitretin's mechanism of action.
• Acitretin likely normalizes keratinocyte differentiation in psoriasis through a STAT1 and STAT3-dependent mechanism, reducing aberrant cell proliferation.